Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
bluebird bio
bluebird bio
Activities:
Research & Development
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Manufacturing
Minaris to manufacture Bluebird Bio therapy for CALD
Early Cerebral Adrenoleukodystrophy is a life-threatening progressive neurodegenerative disease
Ingredients
Refined commercial production spec gets gene therapy EMA go-ahead
US-based Bluebird Bio is working with German apceth Biopharma for commercial manufacturing of its one-time thalassemia therapy that is approved in the EU, not the US
Regulatory
Apceth bullish on manufacturing deal with bluebird bio
The German CDMO will operate as commercial manufacturer in Europe for Zynteglo, bluebird bio's first gene therapy to gain regulatory approval
Manufacturing
Bluebird bio opens lentiviral vector manufacturing facility
The US company’s first facility will produce clinical and commercial supplies of gene therapy vectors, with room for expansion
Pharmaceutical
Collaboration to develop gamma delta CAR T cell product candidates
bluebird bio and Scottish immunotherapy company TC BioPharm, announced a strategic collaboration and license agreement focused on gamma delta CAR T cells
Research & Development
Lonza and Bluebird Bio announce commercial manufacturing agreement
For Lenti-D and LentiGlobin therapies for severe genetic diseases and T cell-based immunotherapies for cancer
You need to be a subscriber to read this article.
Click here
to find out more.
Research & Development
Homing in on cancer targets
Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach
Subscribe now